Coulter Partners is a global search specialist focused exclusively on life sciences. We are held in the highest regard as trusted adviser to the sector on senior leadership roles in the American, U.K. and European Markets.
We have a combined expertise gained over 25 years in the industry, concentrated in the largest dedicated Life Science team in North America and Europe with 60 consultants working together from 11 offices as a single global P&L.
Our approach is to hire and develop exceptional multi-skilled sector analysts with PhDs, MBAs, deep industry knowledge and an outstanding track record of search at Executive and Board level. Our team culture and personal reward system are founded on commitment to the highest standards of client and candidate service.
Our mission is to impact the industry’s ability to deliver advances in diagnosis, prevention, treatment and management of disease. We do this by bringing the world’s best talent to a broad spectrum of global clients; from multinationals, to small and midcap businesses, as well as to the global investor community, building their own teams and the boards and executive leadership of their portfolio investments.
Recently Completed Searches
Dr. Richard Butt — Chief Executive Officer — Apollo Therapeutics Investment Fund Dr. Michael Mehler — Chief Executive Officer — leon-nanodrugs Dr. Thomas Taapken — Chief Financial Officer — Medigene AG Björn Westberg — Chief Financial Officer — BONESUPPORT Dr. Neil Brewis — Chief Scientific Officer — F-star Dr. Alexander Scheer — Chief Scientific Officer — Erytech Pharma Viki Wills — Director of Clinical Operations — BerGenBio Dr. Prabhavathi Fernandes — Member of Supervisory Board — Curetis N.V. Dr. Giles Campion — Chief Medical Officer — Albumedix Elmar Schnee — Chief Operating Officer — MindMaze
HUNT SCANLON NEWSWIRE BRIEFINGS
Executive search firm Coulter Partners has placed Dr. Sonia Quaratino as chief medical officer of Kymab Group, a human monoclonal antibody biopharmaceutical company. She will manage the clinical development of the organization’s expanding therapeutic antibody portfolio. Dr. Quaratino is an immunologist and joins Kymab from Novartis, where she served as global clinical program leader – transitional clinical oncology, responsible for
Executive search firm Coulter Partners has opened a new office in Zurich and tapped Phillipp Buis to serve as executive director. This strategic expansion at the firm enhances Coulter Partners’ presence in this key Swiss life sciences market, while also strengthening its German, Austrian, and international networks further. Mr. Buis joins the Swiss based team at Coulter Partners to
Executive search firm Coulter Partners has placed Dr. Giles Campion as chief medical officer (CMO) of Albumedix. Dr. Campion brings with him more than 25 years of experience in drug development from both large pharma and biotech companies having worked in senior development positions in the U.S. as well as Europe. Previously, he was senior vice president of research and development
Executive search firm Coulter Partners has recruited Dr. Alexander Scheer, Ph.D. as chief scientific officer of ERYTECH Pharma. The search was led by director Dr. Kay Wardle, working with managing partner Arnaldo De Lisio. “Coulter Partners was asked to recruit a successor to the founding CSO,” said Dr. Wardle. “This is a critical hire for the organization, requiring someone to
Executive search firm Coulter Partners has recruited Allene M. Diaz as a non-executive director at ERYTECH Pharma. Ms. Diaz will initially attend all board of directors meetings in an advisory capacity. ERYTECH will nominate Ms. Diaz to serve as a voting board member in January in anticipation of the next general shareholders’ meeting. Ms. Diaz has more
LONDON, U.K., January 26, 2017 — Coulter Partners was delighted to partner with Kymab to secure the appointment of Dr Arndt Schottelius as its first Executive Vice President Research & Development. Kymab Group Limited is a leading biopharmaceutical group focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary Kymouse™ antibody platform. Dr
LONDON, U.K., January 25, 2017 — Coulter Partners was delighted to partner withleon-nanodrugs GmbH to secure the appointment of pharma expert Michael Mehler, Sc.D. as new CEO of the Munich based company and its U.S. subsidiary leon-nanodrugs Inc. He succeeds Dr. Theron Odlaug who will continue to serve the company on the Supervisory Board. leon-nanodrugs GmbH, headquartered in Munich,
LONDON, U.K., January 23, 2017 — Coulter Partners was delighted to partner with BONESUPPORT AB to secure the appointment of Björn Westberg as Chief Financial Officer and Director. A Scandinavian medical technology company, BONESUPPORT AB is an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery. Mr
LONDON, U.K., January 4, 2017 — Coulter Partners was delighted to partner with Albumedix to secure the appointment of Dr. Giles Campion as Chief Medical Officer. Albumedix develops albumin-enabled therapeutics using its albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Using its products and technologies, Albumedix is advancing
LONDON, U.K., December 1, 2016 — Coulter Partners was delighted to partner once again with Medigene AG to secure the appointment of Dr. Thomas Taapken as Chief Financial Officer. Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The Company develops highly innovative, complementary treatment platforms to target various